Auteurs
Checkpoint
Ncbi
Racine
Checkpoint
Ncbi
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Naoyuki Hirakata »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Naoyasu Ueda < Naoyuki Hirakata < Naoyuki Katayama  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000639 (2012) Shunsuke Mori [Japon] ; Yukitaka Ueki ; Naoyuki Hirakata ; Motohiro Oribe ; Toshihiko Hidaka ; Kazunori OishiImpact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis.
000738 (2013) Shunsuke Mori [Japon] ; Yukitaka Ueki ; Yukihiro Akeda ; Naoyuki Hirakata ; Motohiro Oribe ; Yoshiki Shiohira ; Toshihiko Hidaka ; Kazunori OishiPneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.
000C97 (2015) Shunsuke Mori [Japon] ; Tamami Yoshitama [Japon] ; Toshihiko Hidaka [Japon] ; Naoyuki Hirakata [Japon] ; Yukitaka Ueki [Japon]Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study).
001615 (2017) Shunsuke Mori [Japon] ; Tamami Yoshitama [Japon] ; Toshihiko Hidaka [Japon] ; Fumikazu Sakai [Japon] ; Mizue Hasegawa ; Yayoi Hashiba [Japon] ; Eiichi Suematsu [Japon] ; Hiroshi Tatsukawa [Japon] ; Akinari Mizokami [Japon] ; Shigeru Yoshizawa [Japon] ; Naoyuki Hirakata [Japon] ; Yukitaka Ueki [Japon]Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.
001726 (2017) Shunsuke Mori ; Tamami Yoshitama ; Naoyuki Hirakata ; Yukitaka UekiPrevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals
001E19 (2019) Shunsuke Mori [Japon] ; Tamami Yoshitama [Japon] ; Yasuyo Abe [Japon] ; Toshihiko Hidaka [Japon] ; Naoyuki Hirakata [Japon] ; Kiyoshi Aoyagi [Japon] ; Yukitaka Ueki [Japon]Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Naoyuki Hirakata" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Naoyuki Hirakata" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Naoyuki Hirakata
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021